The hepatitis C virus (HCV), a single-stranded RNA virus of the family Flaviviridae with six major genotypes, infects up to 150 million people worldwide. Chronic hepatitis C virus infection causes progressive liver fibrosis, which can lead to cirrhosis and hepatocellular carcinoma. There is now an e ffective oral regimen . New research findings are summarized in this short video from NEJM: This is a ribavirin-free single-tablet regimen. There 2 medications in the single tablet: - Sofosbuvir is a nucleotide analogue inhibitor of the HCV NS5B polymerase approved for the treatment of HCV in combination with a variety of other agents, including NS5A inhibitors, ribavirin, and peginterferon–ribavirin. - Velpatasvir is a new pangenotypic HCV NS5A inhibitor with antiviral activity against HCV replicons in genotypes 1 through 6. The rate of sustained virologic response among patients receiving sofosbuvir–velpatasvir was 99%. See the NEJM article, "Sofosbuvir and Velpatasvir for HCV Geno